US EditionPublished • loading... • Updated
Lupin launches Dapagliflozin tablets in the United States
Summary by CDR – Chain Drug Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Lupin launches Dapagliflozin tablets in the United States
MUMBAI, India and NAPLES, Fla. — Global pharmaceutical leader Lupin Limited today announced the launch of Dapagliflozin Tablets, 5 mg and 10 mg, in the United States following the approval for its Abbreviated New Drug Application from the U.S. FDA as bioequivalent to Farxiga® for the indications in the approved labeling.To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin*Safe Harbor StatementFarxiga …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
